NASDAQ:ALLO

Allogene Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy ALLO

*Your capital is at risk

$2.00

-0.0500 (-2.44%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

ALLO Prediction Chart

ALLO Predictions History

Latest community submissions for ALLO.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Aug 31, 2020	$35.27 -1.07%	$35.65	X	98.93%	2
iHustle84 Pro	Aug 31, 2020	$33.45 -6.17%	$35.65	X	93.83%	0
AJ172511	Aug 31, 2020	Bearish	$35.65	X	—	0
2poJeff Pro	May 27, 2020	$49.90 +1.86%	$48.99	X	98.14%	1
Money	May 15, 2020	$41.00 -8.71%	$44.91	X	91.29%	0
Alan Pro @Alan.115878	Aug 12, 2019	$30.73 +4.20%	$29.49	X	95.80%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ALLO with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT ALLOGENE THERAPEUTICS INC.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by